Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer-Reference-Cited by-同舟云学术

Clinical perspective: Antibody-drug conjugates for the treatment of HER2-positive breast cancer

Published:2023-07 Issue:7 Volume:31 Page:1874-1903
ISSN:1525-0016
Container-title:Molecular Therapy
language:en
Short-container-title:Molecular Therapy

Author:

Najminejad Zohreh,Dehghani Fatemeh,Mirzaei Yousef,Mer Ali Hussein,Saghi Seyyed Amirreza,Abdolvahab Mohadeseh Haji,Bagheri Nader,Meyfour Anna,Jafari Ameneh,Jahandideh Saeed,Gharibi Tohid,Amirkhani Zahra,Delam Hamed,Mashatan Noushin,Shahsavarani Hosein,Abdollahpour-Alitappeh Meghdad

Publisher

Elsevier BV

Subject

Drug Discovery,Pharmacology,Genetics,Molecular Biology,Molecular Medicine

Reference121 articles.

1. Mortality by cause for eight regions of the world: global burden of disease study;Murray;Lancet,1997

2. Epidemiology of breast cancer;Key;Lancet Oncol.,2001

3. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA. Cancer J. Clin.,2021

4. Global patterns of breast cancer incidence and mortality: a population-based cancer registry data analysis from 2000 to 2020;Lei;Cancer Commun.,2021

5. Drug uptake-based chemoresistance in breast cancer treatment;Muley;Biochem. Pharmacol.,2020

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical and preclinical advances in PSMA-Directed Antibody-Drug conjugates (ADCs): Current status and hope for the future;Bioorganic Chemistry;2024-12

2. Targeting HER2 in solid tumors: Unveiling the structure and novel epitopes;Cancer Treatment Reviews;2024-11

3. DNA self-assembly-mediated high drug-antibody ratio ADC platform for targeted tumor therapy and imaging;Nano Today;2024-10

4. Double agents in immunotherapy: Unmasking the role of antibody drug conjugates in immune checkpoint targeting;Critical Reviews in Oncology/Hematology;2024-10

5. Nectin-4-directed antibody-drug conjugates (ADCs): Spotlight on preclinical and clinical evidence;Life Sciences;2024-09